Unsurprisingly strong Q2 21
21/07/21 -"Sartorius announced expected Q2/H1 21 earnings, which had little element of surprise following the preliminary announcement on 6 July. H1 sales (+60.1%), EBITDA margins (34.1%) as well as guidance ..."
Pages
63
Language
English
Published on
21/07/21
You may also be interested by these reports :
10/07/26
Following Thermo Fisher’s unsuccessful bid in 2020, Qiagen gradually restructured its business, focusing on non-COVID growth avenues. However, in ...
10/07/26
Non Pharma Health stocks have long been suffering. The sector has lost 39% ytd, not helped by EssilorLuxottica’s -35% correction. EL’s connected ...
23/06/26
There’s an interesting paradox at the heart of Sartorius Stedim Biotech’s (SSB; ADD; France) investment case. Since our last push in February 2025, ...
03/06/26
Despite a reduction in our target price, as discussed in the EPS section, our positive recommendation on Qiagen remains unchanged. This optimism is ...